Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 12/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964419 | 0.92 | CD274 (0.41) | DRD2DRD1DRD4DRD5CD274 | |
| SCHEMBL9934461 | 0.91 | ADRA2A (0.41) | CD274PDCD1 | |
| SCHEMBL9935737 | 0.87 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL9964441 | 0.86 | CD274 (0.35) | DRD2DRD1DRD4DRD5CD274 | |
| SCHEMBL9964414 | 0.86 | FFAR1 (0.38) | DRD2DRD1DRD4DRD5CD274 | |
| SCHEMBL9934065 | 0.85 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL9964425 | 0.84 | CD274 (0.39) | DRD2DRD1DRD4DRD5CD274 | |
| SCHEMBL9964444 | 0.84 | CD274 (0.36) | DRD2DRD1DRD4DRD5CD274 | |
| SCHEMBL9964452 | 0.84 | FFAR1 (0.45) | CD274PDCD1FFAR1 | |
| SCHEMBL9964394 | 0.84 | FFAR1 (0.44) | DRD2DRD1DRD4DRD5CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| WO-2011078371-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | 持田製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | DRD2 950/4885DRD1 713/4885DRD4 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.